Orexigen Therapeutics to price public offering of common-share units

Proceeds fund working capital and other general corporate purposes

By Devika Patel

Knoxville, Tenn., Dec. 14 - Orexigen Therapeutics, Inc. will price a public offering of units of common shares and 10-year warrants, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Leerink Swann is the bookrunner and will have a 30-day greenshoe option.

Proceeds will be used for working capital and other general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.